Cholesterol, cholesterol lowering agents/statins, and urologic disease: part I - knowing your numbers

Area of Science:

• Urology
• Cardiology
• Public Health

Background:

• Cardiovascular disease (CVD) is the leading cause of mortality worldwide.
• CVD is a significant cause of death in cancer patients, including those with prostate cancer.
• Urology patients often present with conditions that may share underlying mechanisms with CVD.

Purpose of the Study:

• To highlight the importance of assessing cardiovascular disease risk factors in urology.
• To underscore the relevance of CVD markers in managing urologic conditions.
• To emphasize the role of CVD risk assessment in monitoring patient lifestyle changes.

Main Methods:

• Review of existing literature on CVD prevalence and mortality.
• Analysis of the relationship between CVD and common urologic conditions.
• Discussion of the utility of CVD risk markers in urologic patient care.

Main Results:

• CVD is the primary cause of death in the general population and in men with prostate cancer.
• Shared pathophysiological mechanisms may link CVD and urologic conditions like benign prostatic hyperplasia and kidney cancer.
• Monitoring CVD risk markers aids in evaluating the effectiveness of lifestyle interventions in urology.

Conclusions:

• Integrating CVD risk assessment into urologic practice is essential for comprehensive patient care.
• Understanding the links between CVD and urologic diseases can improve patient outcomes.
• Monitoring CVD markers provides a valuable metric for assessing treatment success and promoting healthier lifestyles.